Journal News

MCP: Keeping tabs on protein variants

Laurel Oldach
May 01, 2018

Perhaps you have seen a time-lapse video of a busy city sidewalk. As people come and go, they blur together into a crowd with no distinguishing features. You could count the number of people pushing strollers in each frame, but it might be hard to tell how long one parent has been circling the same block with a colicky baby.

As proteins are made and destroyed in a cell, they tend to blur together too. Many proteomics studies measure with precision the number of copies of each protein species but not how long each one lasts. In a new paper in the journal Molecular & Cellular Proteomics, researchers in Bernard Kuster’s lab at the Technical University of Munich report a new approach to determining the lifespan of a great many proteins, and their alternative isoforms, in large data sets.

“Plenty of research has demonstrated that cancer, neurodegenerative diseases, age-related diseases and even aging per se are associated with altered lifespans of single proteins or a global dysregulation of the cellular recycling machinery,” said lead author Jana Zecha. She compares a cell in which proteins are continuously made and destroyed to “a tiny protein production and recycling machinery.” With colleagues, Zecha set out to measure this factory’s output, determining the rates of production and destruction of many different proteins.

The researchers combined two techniques for telling samples apart by their mass: stable isotope labeling by amino acids in cell culture, or SILAC for short, and tandem mass tag labeling, or TMT. The primary SILAC label enabled a pulse-chase experiment, a way of measuring how much of a new amino acid is taken up after it is added to cells. By combining SILAC with TMT, the researchers could achieve high proteome coverage with high reproducibility and accurate counts of each protein. Then they looked for trends over time. For example, a protein’s rate of synthesis can be measured by how much of the new SILAC label appears over time in its spectrum, and degradation is measured by how much the old label disappears.

Other scientists previously had combined the SILAC and TMT methods, but this data set gave an unusually thorough look at protein lifetimes. The researchers found substantial variability among splice variants of proteins, which no one had yet measured in a data set of this size. Because two splice variants from the same gene have many peptides in common, a data set with many measurements at the peptide level was required.

The approach could offer a better way of understanding the basic biology of disease states with altered protein turnover. The researchers also are interested in modifications occurring after translation that may alter turnover rates.

“A proteomewide measurement of turnover rates of modified peptides is the next logical step for us,” Zecha said.

Laurel Oldach

Laurel Oldach is a science writer for the ASBMB.

Join the ASBMB Today mailing list

Sign up to get updates on articles, interviews and events.

Latest in Science

Science highlights or most popular articles

Branon works to break barriers in science and higher education
ASBMB Annual Meeting

Branon works to break barriers in science and higher education

March 03, 2021

Tess Branon will speak during the Molecular & Cellular Proteomics early career researcher session on proximity-dependent biotinylation at the 2021 ASBMB Annual Meeting.

Brain Injury Awareness Month 2021
Health Observance

Brain Injury Awareness Month 2021

March 01, 2021

In the U.S., about 2.8 million people sustain a traumatic brain injury annually. Learn about recent research on TBI-related dementia, dysfunctional mitochondria and other work powering the march toward better therapies.

The evolution of proteins from mysteries to medicines
Essay

The evolution of proteins from mysteries to medicines

February 27, 2021

An essay in observance of National Protein Day.

'Every experiment and every breakthrough matters'
Health Observance

'Every experiment and every breakthrough matters'

February 26, 2021

An interview with NYMC dean Marina K. Holz, who studies a rare disease that affects women of childbearing age.

Progeria: From the unknown to the first FDA-approved treatment
Health Observance

Progeria: From the unknown to the first FDA-approved treatment

February 25, 2021

Hutchinson–Gilford progeria syndrome is a rare, fatal genetic disease that causes premature aging.

Raising awareness and funding for Pompe disease
Health Observance

Raising awareness and funding for Pompe disease

February 25, 2021

Father-turned-advocate has founded multiple organizations to support families and search for better therapies for people with rare lysosomal storage disorder.